"I want the one for older women" — extending the human papillomavirus vaccine population base

Jeffrey H J Tan and Michael A Quinn
Med J Aust 2008; 189 (9): . || doi: 10.5694/j.1326-5377.2008.tb02158.x
Published online: 3 November 2008

To the Editor: Wain’s criticism of the Australian Therapeutic Goods Administration (TGA) approval of the bivalent vaccine, Cervarix (GlaxoSmithKline), suggesting it did not adhere to World Health Organization guidelines,1 should not detract from the potential benefits of human papillomavirus (HPV) vaccination in women over 26 years of age.

  • Jeffrey H J Tan
  • Michael A Quinn

  • Oncology and Dysplasia Unit, Royal Women’s Hospital, Melbourne, VIC.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.